Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374093 | 0.84 | MEN1 (0.68) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL13464773 | 0.83 | KDM4E (0.55) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL19145136 | 0.82 | KDM4E (0.54) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL14122007 | 0.82 | SETD7 (0.52) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL14121985 | 0.82 | SETD7 (0.52) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL14121618 | 0.82 | SETD7 (0.52) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL14122216 | 0.81 | KDM4E (0.53) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL8695092 | 0.79 | KDM4E (0.52) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL14122068 | 0.79 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2CHRM2 | |
| SCHEMBL15149504 | 0.79 | GPR119 (0.51) | GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696937-B1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-20130102615-A1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-25 | — | — | US | disclosed |
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1943221-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | Brystol-Myers Squibb Company (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2007041616-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041616-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102615-A1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | CD4, TAF15, ACIN1 | KDM4E 2352/4885PKM 2385/4885GPR119 2873/4885 |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | IDO1, IDO2, EIF2AK2 | KDM4E 1588/4885PKM 2789/4885GPR119 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.